Ryufin

LNA Santé

France · FR0004170017 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Is it growing?Good
Revenue +13% in the year to Dec 31, 2025, on the year before.
Is it a good business?Fair
It earned 7.3% on its shareholders' equity in the year to Dec 31, 2025.
Is it safe?To watch
Equity is 21% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€913M

revenue

7.5%

operating margin

€24M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2022Dec 2023Dec 2024Dec 2025
Revenue€728M€736M€807M€913M
Operating profit€64M€63M€62M€69M
Net profit to shareholders€26M€23M€22M€24M
Earnings per share€2.49€2.29€2.13€2.35
Dividend per share€0.43€0.50€0.60€0.65
Cash from operations€103M€98M€110M€99M
Cash€102M€77M€75M€95M
Total assets€1.5B€1.5B€1.5B€1.6B
Equity€299M€309M€324M€341M

What they do

In the company's own words, from the annual report.

Le Groupe présente une activité principale de gestion et d’exploitation d’établissements de santé (soins médicaux et de réadaptation, cliniques psychiatriques, antennes d’hospitalisation à domicile, chirurgie et centres de santé) et de résidences médicalisées pour personnes âgées valides, semi-dépendantes ou dépendantes. Au sein de ses établissements, il offre des prestations de service hôtelières et médicales. Chaque établissement est soumis à autorisation administrative.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.